KR102159601B1 - 심방 확장 또는 재형성을 특징으로 하는 질환을 치료하기 위한 nep 억제제 - Google Patents

심방 확장 또는 재형성을 특징으로 하는 질환을 치료하기 위한 nep 억제제 Download PDF

Info

Publication number
KR102159601B1
KR102159601B1 KR1020157004112A KR20157004112A KR102159601B1 KR 102159601 B1 KR102159601 B1 KR 102159601B1 KR 1020157004112 A KR1020157004112 A KR 1020157004112A KR 20157004112 A KR20157004112 A KR 20157004112A KR 102159601 B1 KR102159601 B1 KR 102159601B1
Authority
KR
South Korea
Prior art keywords
delete delete
nep inhibitor
pharmaceutically acceptable
amino
prodrug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020157004112A
Other languages
English (en)
Korean (ko)
Other versions
KR20150046039A (ko
Inventor
크리스토프 슈마허
토마스 홀브로
Original Assignee
노파르티스 아게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49000959&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR102159601(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 노파르티스 아게 filed Critical 노파르티스 아게
Publication of KR20150046039A publication Critical patent/KR20150046039A/ko
Application granted granted Critical
Publication of KR102159601B1 publication Critical patent/KR102159601B1/ko
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020157004112A 2012-08-24 2013-08-22 심방 확장 또는 재형성을 특징으로 하는 질환을 치료하기 위한 nep 억제제 Ceased KR102159601B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261692911P 2012-08-24 2012-08-24
US61/692,911 2012-08-24
PCT/EP2013/067472 WO2014029848A1 (en) 2012-08-24 2013-08-22 Nep inhibitors for treating diseases characterized by atrial enlargement or remodeling

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020207026971A Division KR20200111822A (ko) 2012-08-24 2013-08-22 심방 확장 또는 재형성을 특징으로 하는 질환을 치료하기 위한 nep 억제제

Publications (2)

Publication Number Publication Date
KR20150046039A KR20150046039A (ko) 2015-04-29
KR102159601B1 true KR102159601B1 (ko) 2020-09-28

Family

ID=49000959

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020157004112A Ceased KR102159601B1 (ko) 2012-08-24 2013-08-22 심방 확장 또는 재형성을 특징으로 하는 질환을 치료하기 위한 nep 억제제
KR1020207026971A Ceased KR20200111822A (ko) 2012-08-24 2013-08-22 심방 확장 또는 재형성을 특징으로 하는 질환을 치료하기 위한 nep 억제제

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020207026971A Ceased KR20200111822A (ko) 2012-08-24 2013-08-22 심방 확장 또는 재형성을 특징으로 하는 질환을 치료하기 위한 nep 억제제

Country Status (26)

Country Link
US (3) US9517226B2 (cg-RX-API-DMAC7.html)
EP (2) EP3943084A1 (cg-RX-API-DMAC7.html)
JP (4) JP6482462B2 (cg-RX-API-DMAC7.html)
KR (2) KR102159601B1 (cg-RX-API-DMAC7.html)
CN (2) CN108685889A (cg-RX-API-DMAC7.html)
AU (1) AU2013304949C1 (cg-RX-API-DMAC7.html)
BR (1) BR112015003067A2 (cg-RX-API-DMAC7.html)
CA (1) CA2882771C (cg-RX-API-DMAC7.html)
CL (1) CL2015000426A1 (cg-RX-API-DMAC7.html)
DK (1) DK2887961T3 (cg-RX-API-DMAC7.html)
ES (1) ES2879550T3 (cg-RX-API-DMAC7.html)
HU (1) HUE054885T2 (cg-RX-API-DMAC7.html)
IL (1) IL237114B (cg-RX-API-DMAC7.html)
MA (1) MA37850A1 (cg-RX-API-DMAC7.html)
MX (1) MX378867B (cg-RX-API-DMAC7.html)
NZ (1) NZ704604A (cg-RX-API-DMAC7.html)
PH (1) PH12015500375A1 (cg-RX-API-DMAC7.html)
PL (1) PL2887961T3 (cg-RX-API-DMAC7.html)
PT (1) PT2887961T (cg-RX-API-DMAC7.html)
RU (1) RU2667643C2 (cg-RX-API-DMAC7.html)
SG (1) SG11201500256UA (cg-RX-API-DMAC7.html)
SI (1) SI2887961T1 (cg-RX-API-DMAC7.html)
TN (1) TN2015000028A1 (cg-RX-API-DMAC7.html)
TW (1) TWI634887B (cg-RX-API-DMAC7.html)
WO (1) WO2014029848A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201500262B (cg-RX-API-DMAC7.html)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
BRPI0711558A2 (pt) 2006-05-04 2011-11-08 Boeringer Ingelheim Internat Gmbh polimorfos
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
PE20140960A1 (es) 2008-04-03 2014-08-15 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
US9034883B2 (en) 2010-11-15 2015-05-19 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
US20130303554A1 (en) 2012-05-14 2013-11-14 Boehringer Ingelheim International Gmbh Use of a dpp-4 inhibitor in sirs and/or sepsis
RU2667643C2 (ru) 2012-08-24 2018-09-21 Новартис Аг Ингибиторы nep для лечения заболеваний, характеризующихся увеличением или ремоделированием предсердия
DK3626270T3 (da) 2013-08-26 2024-01-15 Novartis Ag Behandling af kardiovaskulære sygdomme
US9526728B2 (en) * 2014-02-28 2016-12-27 Boehringer Ingelheim International Gmbh Medical use of a DPP-4 inhibitor
CN106795099B (zh) * 2014-04-10 2019-11-26 南京奥昭生物科技有限公司 用于治疗高血压和心血管疾病的前药和组合物
EP2990800A1 (en) * 2014-08-29 2016-03-02 Fundació Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol Neprilysin as heartfailure (HF) prognostic marker
PL4212152T3 (pl) * 2015-05-11 2025-08-11 Novartis Ag Schemat dawkowania sakubitrylu-walsartanu do leczenia przewlekłej skurczowej niewydolności serca
WO2016193883A1 (en) 2015-05-29 2016-12-08 Novartis Ag Sacubitril and valsartan for treating metabolic disease
CN106309388A (zh) * 2015-06-30 2017-01-11 深圳信立泰药业股份有限公司 一种用于心衰治疗的药物组合物及其制备方法
WO2017006254A1 (en) 2015-07-08 2017-01-12 Novartis Ag Drug combination comprising an angiotensin ii receptor antagonist, a neutral endopeptidase inhibitor and a mineralcorticoid receptor antagonist
CN105997993B (zh) * 2015-07-11 2018-03-30 麦丽芳 一种用于心血管疾病治疗的固体口服型制剂及其制备方法
CN105997994A (zh) * 2015-07-11 2016-10-12 凌莉 一种固体口服型制剂及其制备方法
US10596151B2 (en) 2015-08-28 2020-03-24 Novartis Ag Methods and pharmaceutical compositions for reducing arterial stiffness with a combination of a therapeutic agent blocking the angiotensin receptor and a therapeutic agent inhibiting the NEP enzyme
JP7156945B2 (ja) 2016-02-03 2022-10-19 ノバルティス アーゲー 有機化合物のガレヌス製剤
CN109310697A (zh) 2016-06-10 2019-02-05 勃林格殷格翰国际有限公司 利格列汀和二甲双胍的组合
WO2019008485A1 (en) 2017-07-06 2019-01-10 Mankind Pharma Ltd FIXED DOSE PHARMACEUTICAL COMPOSITION BASED ON VALSARTAN AND SACUBITRIL
UY38072A (es) * 2018-02-07 2019-10-01 Novartis Ag Compuestos derivados de éster butanoico sustituido con bisfenilo como inhibidores de nep, composiciones y combinaciones de los mismos
EP3840746A1 (en) 2018-08-23 2021-06-30 Novartis AG New pharmaceutical use for the treatment of heart failure
WO2020039394A1 (en) 2018-08-24 2020-02-27 Novartis Ag New drug combinations
US11730812B2 (en) 2019-03-08 2023-08-22 Boehringer Ingelheim International Gmbh Anti-IL-36R antibody formulations

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100984939B1 (ko) 2002-01-17 2010-10-01 노파르티스 아게 발사르탄 및 ｎｅｐ 저해제를 포함하는 제약학적 조성물
WO2012027237A1 (en) * 2010-08-24 2012-03-01 Novartis Ag Treatment of hypertension and/or prevention or treatment of heart failure in a mammal receiving anti-coagulant therapy

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3004206A1 (de) 1980-02-06 1981-08-13 Hoechst Ag, 6000 Frankfurt Verfahren zur herstellung von 1-alkyl-1-phenylhydrazinen
DE3005674A1 (de) 1980-02-15 1981-08-20 Ruhr-Zink GmbH, 4354 Datteln Verwendung einer blei-legierung fuer anoden bei der elektrolytischen gewinnung von zink
DE3010374A1 (de) 1980-03-18 1981-10-08 Bayer Ag, 5090 Leverkusen Verfahren zur herstellung von copolymerisaten von styrol und/oder dessen derivaten
US4610816A (en) 1980-12-18 1986-09-09 Schering Corporation Substituted dipeptides as inhibitors of enkephalinases
US4383527A (en) 1981-02-20 1983-05-17 Howmedica, Inc. Device for guiding the insertion of surgical wires into bone tissue
DE3173350D1 (en) 1981-04-24 1986-02-13 Jean Martin Prefabricated unit for the realization of a construction frame
ZA84670B (en) 1983-01-31 1985-09-25 Merck & Co Inc Thiorphan analogs as enkephalinase and angiotensin converting enzyme inhibitors
US4722810A (en) 1984-08-16 1988-02-02 E. R. Squibb & Sons, Inc. Enkephalinase inhibitors
US4749688A (en) 1986-06-20 1988-06-07 Schering Corporation Use of neutral metalloendopeptidase inhibitors in the treatment of hypertension
US4929641B1 (en) 1988-05-11 1994-08-30 Schering Corp Mercapto-acylamino acid antihypertensives
US4740499A (en) 1986-07-28 1988-04-26 Monsanto Company Method of enhancing the bioactivity of atrial peptides
GB8811873D0 (en) 1988-05-19 1988-06-22 Pfizer Ltd Therapeutic agents
GB2218983A (en) 1988-05-27 1989-11-29 Pfizer Ltd Spiro-substituted glutaramides as diuretics
GB8812597D0 (en) 1988-05-27 1988-06-29 Pfizer Ltd Therapeutic agents
EP0361365A1 (en) 1988-09-30 1990-04-04 E.R. SQUIBB & SONS, INC. Aminobenzoic and aminocyclohexane-carboylic acid compounds, compositions, and their method of use
GB8903740D0 (en) 1989-02-18 1989-04-05 Pfizer Ltd Therapeutic agents
EP0443983B1 (de) 1990-02-19 1996-02-28 Ciba-Geigy Ag Acylverbindungen
US5223516A (en) 1990-03-22 1993-06-29 E. R. Squibb & Sons, Inc. 3,3,3-trifluoro-2-mercaptomethyl-N-tetrazolyl substituted propanamides and method of using same
GB9103454D0 (en) 1991-02-19 1991-04-03 Pfizer Ltd Therapeutic agents
US5294632A (en) 1991-05-01 1994-03-15 Ciba-Geigy Corporation Phosphono/biaryl substituted dipetide derivatives
US5250522A (en) 1992-10-09 1993-10-05 Ciba-Geigy Corporation Phosphono/biaryl substituted amino acid derivatives
US5273990A (en) 1992-09-03 1993-12-28 Ciba-Geigy Corporation Phosphono substituted tetrazole derivatives
GB9123353D0 (en) 1991-11-04 1991-12-18 Fujisawa Pharmaceutical Co New mercapto-amide derivatives,processes for the preparation thereof and pharmaceutical composition comprising the same
WO1993010773A1 (en) 1991-12-06 1993-06-10 Schering-Plough S.P.A. Use of neutral endopeptidase inhibitors in the treatment of left ventricular hypertrophy
US5217996A (en) 1992-01-22 1993-06-08 Ciba-Geigy Corporation Biaryl substituted 4-amino-butyric acid amides
DE4233296C1 (de) 1992-10-02 1994-03-31 Heitland Und Petre Int Gmbh Behälter für Kosmetikprodukte
WO1994015908A1 (fr) 1993-01-14 1994-07-21 Yoshitomi Pharmaceutical Industries, Ltd. Derive de propionamide et son utilisation medicinale
JPH06234754A (ja) 1993-02-10 1994-08-23 Dai Ichi Seiyaku Co Ltd 複素環式カルボン酸誘導体
IT1266571B1 (it) 1993-07-30 1997-01-09 Zambon Spa Derivati della beta-mercapto-propanammide utili nel trattamento delle malattie cardiovascolari
JP3576193B2 (ja) 1993-12-03 2004-10-13 第一製薬株式会社 ビフェニルメチル置換バレリルアミド誘導体
US6201002B1 (en) 1997-01-10 2001-03-13 Merck & Co., Inc. Method for reducing mortality with an angiotensin II antagonist
RU2245162C2 (ru) * 2003-01-04 2005-01-27 Козлов Владимир Александрович Способ терапии инфаркта миокарда
MXPA05012299A (es) 2003-05-16 2006-01-30 Novartis Ag Composicion farmaceutica que comprende valsartan.
MY146830A (en) * 2005-02-11 2012-09-28 Novartis Ag Combination of organic compounds
AR057882A1 (es) 2005-11-09 2007-12-26 Novartis Ag Compuestos de accion doble de bloqueadores del receptor de angiotensina e inhibidores de endopeptidasa neutra
KR101589317B1 (ko) 2007-11-06 2016-01-28 노파르티스 아게 안지오텐신 수용체 길항제/차단제 （ａｒｂ） 및 중성 엔도펩티다제 （ｎｅｐ） 억제제의 초구조에 기초한 이중-작용 제약 조성물
RU2667643C2 (ru) 2012-08-24 2018-09-21 Новартис Аг Ингибиторы nep для лечения заболеваний, характеризующихся увеличением или ремоделированием предсердия

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100984939B1 (ko) 2002-01-17 2010-10-01 노파르티스 아게 발사르탄 및 ｎｅｐ 저해제를 포함하는 제약학적 조성물
WO2012027237A1 (en) * 2010-08-24 2012-03-01 Novartis Ag Treatment of hypertension and/or prevention or treatment of heart failure in a mammal receiving anti-coagulant therapy

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Lancet. 2012. Vol.380, pp.1387-1395.

Also Published As

Publication number Publication date
PL2887961T3 (pl) 2021-11-08
IL237114A0 (en) 2015-03-31
CA2882771C (en) 2021-02-23
CL2015000426A1 (es) 2015-10-02
BR112015003067A2 (pt) 2017-07-04
IL237114B (en) 2020-10-29
US20150190376A1 (en) 2015-07-09
RU2018126749A3 (cg-RX-API-DMAC7.html) 2021-12-28
WO2014029848A1 (en) 2014-02-27
US11135192B2 (en) 2021-10-05
RU2015110240A (ru) 2016-10-20
SI2887961T1 (sl) 2021-08-31
JP6482462B2 (ja) 2019-03-13
HUE054885T2 (hu) 2021-10-28
CA2882771A1 (en) 2014-02-27
KR20150046039A (ko) 2015-04-29
US20180200218A1 (en) 2018-07-19
ZA201500262B (en) 2016-09-28
MX378867B (es) 2025-03-11
JP2022020624A (ja) 2022-02-01
CN104602711A (zh) 2015-05-06
PH12015500375A1 (en) 2015-04-20
AU2013304949A1 (en) 2015-02-05
US20170049738A1 (en) 2017-02-23
JP2019069954A (ja) 2019-05-09
MX2015002432A (es) 2015-06-22
HK1205930A1 (en) 2015-12-31
US9517226B2 (en) 2016-12-13
KR20200111822A (ko) 2020-09-29
US9937143B2 (en) 2018-04-10
PT2887961T (pt) 2021-07-28
SG11201500256UA (en) 2015-04-29
RU2018126749A (ru) 2019-03-12
EP2887961A1 (en) 2015-07-01
EP3943084A1 (en) 2022-01-26
RU2667643C2 (ru) 2018-09-21
TWI634887B (zh) 2018-09-11
MA37850A1 (fr) 2018-07-31
NZ704604A (en) 2018-06-29
JP7407508B2 (ja) 2024-01-04
JP2023159114A (ja) 2023-10-31
JP2015526458A (ja) 2015-09-10
CN108685889A (zh) 2018-10-23
AU2013304949C1 (en) 2020-12-24
EP2887961B1 (en) 2021-04-28
TW201414471A (zh) 2014-04-16
TN2015000028A1 (en) 2016-06-29
ES2879550T3 (es) 2021-11-22
DK2887961T3 (da) 2021-07-19
AU2013304949B2 (en) 2016-08-11

Similar Documents

Publication Publication Date Title
JP7407508B2 (ja) 心房拡大又はリモデリングを特徴とする疾患を治療するためのｎｅｐ阻害剤
CN102091330B (zh) 含有缬沙坦和nep抑制剂的药物组合物
US20160206597A1 (en) New Use
EP3626270A1 (en) New use
JP2010536880A (ja) 糖尿病の合併症のための療法
EP4570314A2 (en) Sacubitril-valsartan dosage regimen for treating chronic systolic heart failure
JP6598985B2 (ja) 新規の使用
RU2809222C2 (ru) Ингибиторы nep для лечения заболеваний, характеризующихся увеличением или ремоделированием предсердия
HK40061914A (en) Nep inhibitors for treating diseases characterized by atrial enlargement or remodeling
KR20210032437A (ko) 심부전의 치료를 위한 신규한 약제학적 용도
HK1205930B (en) Nep inhibitors for treating diseases characterized by atrial enlargement or remodeling
Ruilope 14| Vasopeptidase inhibitors

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

A107 Divisional application of patent
GRNT Written decision to grant
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

S14-X000 Exclusive voluntary license recorded

St.27 status event code: A-4-4-S10-S14-lic-X000

J206 Request for trial to confirm the scope of a patent right
PJ0206 Trial to confirm the scope of a patent

St.27 status event code: A-5-5-V10-V11-apl-PJ0206

J204 Request for invalidation trial [patent]
PJ0204 Invalidation trial for patent

St.27 status event code: A-5-5-V10-V11-apl-PJ0204

J204 Request for invalidation trial [patent]
PJ0204 Invalidation trial for patent

St.27 status event code: A-5-5-V10-V11-apl-PJ0204

J206 Request for trial to confirm the scope of a patent right
PJ0206 Trial to confirm the scope of a patent

St.27 status event code: A-5-5-V10-V11-apl-PJ0206

J301 Trial decision

Free format text: TRIAL NUMBER: 2023100001955; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20230531

Effective date: 20230822

PJ1301 Trial decision

St.27 status event code: A-5-5-V10-V15-crt-PJ1301

Decision date: 20230822

Appeal event data comment text: Appeal Kind Category : Confirmation of the scope of right_defensive, Appeal Ground Text : 2159601

Appeal request date: 20230531

Appellate body name: Patent Examination Board

Decision authority category: Office appeal board

Decision identifier: 2023100001955

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

J301 Trial decision

Free format text: TRIAL NUMBER: 2022100002605; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20220919

Effective date: 20230919

PJ1301 Trial decision

St.27 status event code: A-5-5-V10-V15-crt-PJ1301

Decision date: 20230919

Appeal event data comment text: Appeal Kind Category : Confirmation of the scope of right_defensive, Appeal Ground Text : 2159601

Appeal request date: 20220919

Appellate body name: Patent Examination Board

Decision authority category: Office appeal board

Decision identifier: 2022100002605

J301 Trial decision

Free format text: TRIAL NUMBER: 2022100002737; TRIAL DECISION FOR INVALIDATION REQUESTED 20221004

Effective date: 20230922

PJ1301 Trial decision

St.27 status event code: A-5-5-V10-V15-crt-PJ1301

Decision date: 20230922

Appeal event data comment text: Appeal Kind Category : Invalidation, Appeal Ground Text : 2159601

Appeal request date: 20221216

Appellate body name: Patent Examination Board

Decision authority category: Office appeal board

Decision identifier: 2022100003493

Decision date: 20230922

Appeal event data comment text: Appeal Kind Category : Invalidation, Appeal Ground Text : 2159601

Appeal request date: 20221004

Appellate body name: Patent Examination Board

Decision authority category: Office appeal board

Decision identifier: 2022100002737

PC2102 Extinguishment

St.27 status event code: N-4-6-H10-H13-oth-PC2102